Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
47 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Newron Pharmaceuticals S.p.A. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Newron Pharmaceuticals S.p.A. - Product Pipeline Review - 2014', provides an overview of the Newron Pharmaceuticals S.p.A.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Newron Pharmaceuticals S.p.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Newron Pharmaceuticals S.p.A. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Newron Pharmaceuticals S.p.A.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Newron Pharmaceuticals S.p.A.'s pipeline products Reasons to buy - Evaluate Newron Pharmaceuticals S.p.A.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Newron Pharmaceuticals S.p.A. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Newron Pharmaceuticals S.p.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Newron Pharmaceuticals S.p.A. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Newron Pharmaceuticals S.p.A. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Newron Pharmaceuticals S.p.A. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Newron Pharmaceuticals S.p.A. Snapshot 5 Newron Pharmaceuticals S.p.A. Overview 5 Key Information 5 Key Facts 5 Newron Pharmaceuticals S.p.A. - Research and Development Overview 6 Key Therapeutic Areas 6 Newron Pharmaceuticals S.p.A. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Newron Pharmaceuticals S.p.A. - Pipeline Products Glance 11 Newron Pharmaceuticals S.p.A. - Late Stage Pipeline Products 11 Pre-Registration Products/Combination Treatment Modalities 11 Phase III Products/Combination Treatment Modalities 12 Newron Pharmaceuticals S.p.A. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Newron Pharmaceuticals S.p.A. - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Newron Pharmaceuticals S.p.A. - Drug Profiles 16 safinamide 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 priralfinamide 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 pruvanserin 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 sarizotan hydrochloride 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 sNN-0029 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 sNN-0031 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 NW-3509 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Nav1.7 blocker 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Voltage-Gated Calcium Channel Modulators 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Newron Pharmaceuticals S.p.A. - Pipeline Analysis 30 Newron Pharmaceuticals S.p.A. - Pipeline Products by Target 30 Newron Pharmaceuticals S.p.A. - Pipeline Products by Route of Administration 32 Newron Pharmaceuticals S.p.A. - Pipeline Products by Molecule Type 33 Newron Pharmaceuticals S.p.A. - Pipeline Products by Mechanism of Action 34 Newron Pharmaceuticals S.p.A. - Recent Pipeline Updates 35 Newron Pharmaceuticals S.p.A. - Dormant Projects 41 Newron Pharmaceuticals S.p.A. - Discontinued Pipeline Products 42 Discontinued Pipeline Product Profiles 42 pruvanserin 42 sarizotan hydrochloride 42 Newron Pharmaceuticals S.p.A. - Company Statement 43 Newron Pharmaceuticals S.p.A. - Locations And Subsidiaries 45 Head Office 45 Other Locations & Subsidiaries 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 47 Disclaimer 47
List of Tables Newron Pharmaceuticals S.p.A., Key Information 5 Newron Pharmaceuticals S.p.A., Key Facts 5 Newron Pharmaceuticals S.p.A. - Pipeline by Indication, 2014 8 Newron Pharmaceuticals S.p.A. - Pipeline by Stage of Development, 2014 9 Newron Pharmaceuticals S.p.A. - Monotherapy Products in Pipeline, 2014 10 Newron Pharmaceuticals S.p.A. - Pre-Registration, 2014 11 Newron Pharmaceuticals S.p.A. - Phase III, 2014 12 Newron Pharmaceuticals S.p.A. - Phase II, 2014 13 Newron Pharmaceuticals S.p.A. - Phase I, 2014 14 Newron Pharmaceuticals S.p.A. - Preclinical, 2014 15 Newron Pharmaceuticals S.p.A. - Pipeline by Target, 2014 31 Newron Pharmaceuticals S.p.A. - Pipeline by Route of Administration, 2014 32 Newron Pharmaceuticals S.p.A. - Pipeline by Molecule Type, 2014 33 Newron Pharmaceuticals S.p.A. - Pipeline Products by Mechanism of Action, 2014 34 Newron Pharmaceuticals S.p.A. - Recent Pipeline Updates, 2014 35 Newron Pharmaceuticals S.p.A. - Dormant Developmental Projects,2014 41 Newron Pharmaceuticals S.p.A. - Discontinued Pipeline Products, 2014 42 Newron Pharmaceuticals S.p.A., Subsidiaries 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.